DE1165606B - Process for the production of aqueous solutions of gelatin derivatives - Google Patents
Process for the production of aqueous solutions of gelatin derivativesInfo
- Publication number
- DE1165606B DE1165606B DEF35339A DEF0035339A DE1165606B DE 1165606 B DE1165606 B DE 1165606B DE F35339 A DEF35339 A DE F35339A DE F0035339 A DEF0035339 A DE F0035339A DE 1165606 B DE1165606 B DE 1165606B
- Authority
- DE
- Germany
- Prior art keywords
- gelatin
- solution
- aqueous solutions
- production
- gelatin derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920000159 gelatin Polymers 0.000 title claims description 18
- 235000019322 gelatine Nutrition 0.000 title claims description 18
- 108010010803 Gelatin Proteins 0.000 title claims description 17
- 239000008273 gelatin Substances 0.000 title claims description 17
- 235000011852 gelatine desserts Nutrition 0.000 title claims description 17
- 238000000034 method Methods 0.000 title claims description 7
- 239000007864 aqueous solution Substances 0.000 title claims description 4
- WUIJTQZXUURFQU-UHFFFAOYSA-N 1-methylsulfonylethene Chemical compound CS(=O)(=O)C=C WUIJTQZXUURFQU-UHFFFAOYSA-N 0.000 claims description 11
- 230000007062 hydrolysis Effects 0.000 claims description 4
- 238000006460 hydrolysis reaction Methods 0.000 claims description 4
- 239000007857 degradation product Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000012670 alkaline solution Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000003633 blood substitute Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- JBIJLHTVPXGSAM-UHFFFAOYSA-N 2-naphthylamine Chemical compound C1=CC=CC2=CC(N)=CC=C21 JBIJLHTVPXGSAM-UHFFFAOYSA-N 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- -1 aromatic Bis-vinyl sulfones Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Verfahren zur Herstellung wäßriger Lösungen von Gelatinederivaten Es ist bekannt, daß man durch die Umsetzung von Gelatine mit Glyoxal und anschließende Oxydation mit Wasserstoffsuperoxyd eine wäßrige Lösung hochmolekularer Polypeptidderivate erhält, die als Blutersatzflüssigkeit therapeutisch verwendet werden kann. Auch Umsetzungsprodukte aus Gelatine und Säureanhydriden wurden für den gleichen Verwendungszweck bereits eingesetzt. Die beiden Verfahren zur Herstellung dieser Blutersatzflüssigkeiten haben den Nachteil, daß man die Gelatine mit sehr aggressiven Substanzen umsetzen muß und daß das Molekulargewicht des Umsetzungsproduktes im Verlauf dieser Reaktionen weit stärker gesenkt wird, als es im Interesse einer ausreichenden Verweilzeit im Organismus wünschenswert ist.Process for the preparation of aqueous solutions of gelatin derivatives It is known that by reacting gelatin with glyoxal and then Oxidation with hydrogen peroxide an aqueous solution of high molecular weight polypeptide derivatives which can be used therapeutically as a blood substitute fluid. Even Reaction products of gelatin and acid anhydrides have been used for the same purpose already used. The two methods of making these blood substitute fluids have the disadvantage that you react the gelatin with very aggressive substances must and that the molecular weight of the reaction product in the course of these reactions is reduced far more than it is in the interests of sufficient residence time in the Organism is desirable.
Es wurde nun gefunden, daß man therapeutisch als Blutersatzflüssigkeit verwendbare, gut wasserlösliche Gelatinederivate erhalten kann, wenn man in an sich bekannter Weise Gelatine oder ihre durch teilweise Hydrolyse erhaltenen Abbauprodukte mit Vinylmethylsulfon in wäßriger alkalischer Lösung umsetzt. Anschließend können die als Nebenprodukte entstandenen Salze oder sonstigen niedermolekularen Anteile durch Dialyse entfernt werden.It has now been found that it can be used therapeutically as a blood substitute fluid usable, water-soluble gelatin derivatives can be obtained if one in itself known way gelatine or its degradation products obtained by partial hydrolysis Reacts with vinyl methyl sulfone in aqueous alkaline solution. Then you can the salts or other low molecular weight fractions formed as by-products can be removed by dialysis.
Zwar ist die Anlagerung von ß-Naphthylamin an die Doppelbindung des Vinyl-p-tolylsulfons bekannt, jedoch war es nicht ohne weiteres vorauszusehen, daß man durch die Umsetzung von Gelatine oder ihrer durch teilweise Hydrolyse erhaltenen Abbauprodukte mit Vinylmethylsulfon zu wasserlöslichen, im Organismus gut verträglichen Derivaten kommen würde, da insbesondere die Umsetzung von Gelatine mit aromatischen Bis-vinylsulfonen als Verfahren zur Härtung von Gelatine beschrieben wird.It is true that the addition of ß-naphthylamine to the double bond of the Vinyl-p-tolylsulfons known, but it was not easily foreseen that obtained by reacting gelatin or its partial hydrolysis Decomposition products with vinyl methyl sulfone to water-soluble, well-tolerated in the organism Derivatives would come, in particular, the reaction of gelatin with aromatic Bis-vinyl sulfones is described as a process for hardening gelatin.
Die eriindungsgemäße Umsetzung der Gelatine oder ihrer durch teilweise Hydrolyse erhaltenen Abbauprodukte mit Vinylmethylsulfon ermöglicht es, die Gelierungstemperatur der Lösung auch bei Molekulargewichten zwischen 30 000 und 60 000 so weit zu senken, daß die Lösungen bei Zimmertemperatur flüssig sind und ohne Schwierigkeiten infundiert werden können.The inventive implementation of the gelatin or its partial Hydrolysis of the degradation products obtained with vinyl methyl sulfone enables the gelation temperature to reduce the solution so far, even with molecular weights between 30,000 and 60,000, that the solutions are liquid at room temperature and infused without difficulty can be.
Nach einem bevorzugten Verfahren für die Umsetzung tropft man Vinylmethylsulfon in die gut gerührte, mit etwas Natronlauge auf einen px-Wert von 8 bis 9 eingestellte Lösung der Gelatine bei etwa 80'C ein. Man kann den Ablauf der Reaktion durch Messung der Viskosität der Lösung verfolgen und auf diese Weise auch die Viskosität der endgültigen Lösung auf den gewünschten Wert einstellen.According to a preferred method for the reaction, vinyl methyl sulfone is added dropwise in the well-stirred, adjusted to a px value of 8 to 9 with a little sodium hydroxide solution Solution of the gelatin at about 80'C. One can measure the course of the reaction track the viscosity of the solution and in this way also the viscosity of the Adjust the final solution to the desired value.
Nach der Beendigung der Anlagerung entfernt man die entstandenen Salze und niedermolekularen Anteile sowie die überschüssige Natronlauge vorzugsweise durch die Dialyse mit Wasser, wobei zur Beschleunigung des Vorgangs erhöhte Temperatur oder mechanische Bewegung angewendet werden kann. Die Reinigung kann auch durch Fällungsreaktionen oder ähnliche bekannte Maßnahmen erfolgen.After the addition has ended, the salts formed are removed and low molecular weight fractions and the excess sodium hydroxide solution preferably through dialysis with water, with increased temperature to accelerate the process or mechanical movement can be applied. Cleaning can also be done by Precipitation reactions or similar known measures take place.
Die dialysierte Lösung wird auf einen Gehalt von etwa 3 bis 80/, Trockensubstanz eingestellt. Für die Verwendung als Blutersatzflüssigkeit ist der Zusatz von kleinen Mengen anorganischer Salze erforderlich. Man gibt z. B. 0,85 °/o Kochsalz oder die entsprechende Menge eines physiologischen Salzgemisches zu. Die fertige Lösung kann dann unter sterilen Bedingungen in Ampullen abgefüllt und in dieser Form bis zur Verwendung gelagert werden.The dialyzed solution is adjusted to a content of about 3 to 80 % dry matter. For use as a blood substitute fluid, the addition of small amounts of inorganic salts is required. One gives z. B. 0.85% table salt or the corresponding amount of a physiological salt mixture. The finished solution can then be filled into ampoules under sterile conditions and stored in this form until use.
Die erhaltenen Lösungen haben vor den synthetischen Blutersatzpräparaten, z. B. der Polyvinylpyrrolidonlösung, den Vorteil, daß sie im Organismus nach einiger Zeit abgebaut werden, sofern sie nicht ausgeschieden wurden. Andererseits ist die Verweilzeit im Körper bei Verabreichung von Präparaten mit ausreichend hohem Molekulargewicht so groß, daß ein hinreichender therapeutischer Effekt über genügend lange Zeit erreicht werden kann. So besitzen die erhaltenen Lösungen im Tierversuch (Kaninchen) eine therapeutisch günstige längere Verweilzeit im Organismus als die aus der deutschen Auslegeschrift 1038 239 bekannte Blutplasmaersatzlösung, die durch Umsetzung von Gelatine mit N-Methylglucamin hergestellt worden ist.The solutions obtained have before the synthetic blood substitutes, z. B. the polyvinylpyrrolidone solution, the advantage that they are broken down in the organism after some time, provided that they have not been excreted. On the other hand, when preparations with a sufficiently high molecular weight are administered, the residence time in the body is so great that a sufficient therapeutic effect can be achieved over a sufficiently long time. Thus, in animal experiments (rabbits), the solutions obtained have a therapeutically beneficial longer residence time in the organism than the blood plasma replacement solution known from German Auslegeschrift 1038 239, which has been produced by reacting gelatin with N-methylglucamine.
Beispiel l Je 50 g Gelatine werden in 500 ccm Wasser gelöst,
die Lösung durch Zugabe von Natronlauge auf einen pH-Wert von 9 eingestellt und
unter Rühren bei 80°C,
die in der Tabelle angegebenen Mengen Vinylmethylsulfon
innerhalb einer Viertelstunde eingetropft. Die Umsetzung ist nach etwa 3 Stunden
beendet.
Ausbeute: 44 g Trockensubstanz mit 1,950/0 S = 6,5% gebundenem Vinylmethylsulfon. Die unter sterilen Bedingungen hergestellte 5%ige Lösung in physiologischer Kochsalzlösung hat il", = 2,09 und einen Gelierpunkt von -1-8°C.Yield: 44 g dry substance with 1.950 / 0 S = 6.5% bound vinyl methyl sulfone. The 5% solution in physiological saline solution prepared under sterile conditions has il "= 2.09 and a gel point of -1-8 ° C.
Claims (1)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DEF35339A DE1165606B (en) | 1961-11-11 | 1961-11-11 | Process for the production of aqueous solutions of gelatin derivatives |
GB4244562A GB951578A (en) | 1961-11-11 | 1962-11-09 | Therapeutically-useful proteinaceous derivatives |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DEF35339A DE1165606B (en) | 1961-11-11 | 1961-11-11 | Process for the production of aqueous solutions of gelatin derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
DE1165606B true DE1165606B (en) | 1964-03-19 |
Family
ID=7095959
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DEF35339A Pending DE1165606B (en) | 1961-11-11 | 1961-11-11 | Process for the production of aqueous solutions of gelatin derivatives |
Country Status (2)
Country | Link |
---|---|
DE (1) | DE1165606B (en) |
GB (1) | GB951578A (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE635298C (en) * | 1934-06-16 | 1936-09-22 | I G Farbenindustrie Akt Ges | Process for the production of organic sulfur compounds |
DE1038239B (en) * | 1956-12-06 | 1958-09-04 | Merck Ag E | Process for the preparation of solutions for blood plasma replacement |
-
1961
- 1961-11-11 DE DEF35339A patent/DE1165606B/en active Pending
-
1962
- 1962-11-09 GB GB4244562A patent/GB951578A/en not_active Expired
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE635298C (en) * | 1934-06-16 | 1936-09-22 | I G Farbenindustrie Akt Ges | Process for the production of organic sulfur compounds |
DE1038239B (en) * | 1956-12-06 | 1958-09-04 | Merck Ag E | Process for the preparation of solutions for blood plasma replacement |
Also Published As
Publication number | Publication date |
---|---|
GB951578A (en) | 1964-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE1165606B (en) | Process for the production of aqueous solutions of gelatin derivatives | |
DE1192635B (en) | Process for the production of bismuth pectinate | |
DE2117250A1 (en) | Contrast media for radiography | |
DE907293C (en) | Process for the preparation of polysulfuric acid esters and salts thereof | |
DE951228C (en) | Process for stabilizing an adrenocorticotropic preparation | |
DE2002492A1 (en) | Process for the production of sialoglobin sulfate | |
DE323596C (en) | Process for the production of a durable, colloidally soluble silica-amylodextrin preparation | |
DE1179944B (en) | Process for the preparation of a blood substitute | |
DE922736C (en) | Process for the preparation of polyurea derivatives | |
DE1922578C3 (en) | 4,7,10-trioxatrldecane-1,13-dioyibis- (3-carboxy-2,4,6-triiodo-anilide) and its salts, processes for the preparation of these compounds and X-ray contrast media containing these compounds | |
DE629841C (en) | Process for the preparation of an aqueous quinine solution for injection purposes | |
DE2507223C3 (en) | Collagen product and method of making the collagen product | |
AT166930B (en) | Process for the preparation of injection solutions | |
DE1221643C2 (en) | METHOD FOR PRODUCING HUMANHISTAMINE AZO ALBUMINES | |
DE378214C (en) | Process for the production of protein degradation products | |
DE808357C (en) | Process for the production of adhesive, colloidal lactalbuminate solutions | |
DE713471C (en) | Process for the preparation of a water-soluble acetylsalicylic acid salt | |
DE651434C (en) | Method of preventing denaturation of protein medicinal products dissolved in water | |
DE945236C (en) | Process for the production of water-soluble bismuth compounds of ª ‡ -oxy-ª ‡ -phosphono-propionic acid | |
DE605074C (en) | Process for the preparation of compounds of sulfhydryl keratinic acid and similar reduced degradation products of keratin with organic compounds containing arsenic | |
DE513205C (en) | Process for the preparation of derivatives of the aminoarylantimony compounds | |
CH315463A (en) | Process for the preparation of a blood plasma replacement fluid | |
DE2157622C3 (en) | Process for the preparation of an anti-lipemic substance from mammalian organs | |
AT258466B (en) | Method and reagent for the determination of human chorionic gonadotrophin | |
DE1914081A1 (en) | Antistreptolysin reagent for diagnosis in - rheumatic cases |